CDH1 and ductal breast carcinoma in situ: The use of immunohistochemistry with aberrant E-Cadherin staining combined with morphological criteria led to an excellent agreement (86.9%) of correctly classifying in situ or invasive lobular carcinomas and rule out morphological differential diagnoses of duct lesions such as solid-type DCIS or invasive ductal carcinomas (Choi et al. 2008).